Jarisch-Herxheimer Reaction: Causes and Treatment

What is the Jarisch-Herxheimer Reaction?

The Jarisch-Herxheimer reaction (also known as the Herxheimer reaction) is an acute, self-limiting systemic response of the body that typically occurs within two to eight hours after initiating antibiotic treatment for certain bacterial infections. It was named after physicians Adolf Jarisch and Karl Herxheimer, who independently described it in the late 19th and early 20th centuries. Importantly, this reaction is not an allergic response to the antibiotic itself, but rather a consequence of the rapid destruction of large numbers of bacteria in the body.

Causes and Mechanism

When certain antibiotics are administered, large quantities of bacteria are killed in a short period of time. This rapid bacterial death leads to the release of bacterial cell wall components and so-called endotoxins into the bloodstream. These substances trigger a strong activation of the immune system, causing the release of large amounts of pro-inflammatory signaling molecules called cytokines -- including TNF-alpha, interleukin-6, and interleukin-8. This immune cascade is responsible for the characteristic symptoms of the reaction.

The Jarisch-Herxheimer reaction occurs most commonly in the following infectious diseases:

• Syphilis -- the most classic and well-documented cause
• Lyme disease -- infection with Borrelia burgdorferi, transmitted by tick bites
• Relapsing fever -- caused by Borrelia recurrentis
• Leptospirosis
• Q fever
• Other spirochetal infections

Symptoms

Symptoms typically appear within a few hours after the first dose of antibiotic and usually resolve within 12 to 24 hours. Common signs include:

• Sudden fever spike (often up to 40 degrees Celsius)
• Chills and profuse sweating
• Headache and muscle aches
• Skin rash or temporary worsening of existing skin lesions
• Low blood pressure (hypotension)
• Rapid heart rate (tachycardia)
• General malaise and feeling unwell

In rare cases, the reaction can be more severe, particularly in patients with pre-existing heart conditions or in those being treated for relapsing fever.

Diagnosis

The diagnosis of the Jarisch-Herxheimer reaction is primarily clinical, based on the medical history and observed symptoms. The key diagnostic clue is the temporal relationship between the first administration of antibiotics and the onset of symptoms. Laboratory values may show transiently elevated inflammatory markers (CRP, white blood cell count), but these are not specific to this reaction.

It is crucial to distinguish the Herxheimer reaction from an antibiotic allergy or a worsening of the underlying infection, as the appropriate clinical response differs significantly in each case.

Treatment and Management

In most cases, the Jarisch-Herxheimer reaction is self-limiting and resolves without specific treatment. The following measures can help relieve symptoms:

• Antipyretic medications (fever-reducing drugs such as paracetamol or ibuprofen) for symptom control
• Adequate fluid intake and hydration
• Rest and reduced physical activity
• Close monitoring of vital signs, especially in high-risk patients

Antibiotic therapy should generally not be discontinued, as the reaction is a sign that the treatment is working. In severe cases -- particularly in relapsing fever -- inpatient monitoring and intensive care may be necessary. The prophylactic use of corticosteroids is controversial and is not routinely recommended.

Prognosis

In most patients, the Jarisch-Herxheimer reaction is mild to moderate and resolves completely within 24 hours. Severe or life-threatening courses are rare but can occur, particularly in relapsing fever or in immunocompromised individuals. Timely recognition and appropriate symptomatic management are key to a good clinical outcome.

References

1. Belum G.R. et al. - The Jarisch-Herxheimer reaction. Travel Medicine and Infectious Disease, 2013; 11(4): 231-237. PubMed.
2. Butler T. - The Jarisch-Herxheimer Reaction After Antibiotic Treatment of Spirochetal Infections: A Review of Recent Cases and Our Understanding of Pathogenesis. The American Journal of Tropical Medicine and Hygiene, 2017; 96(1): 46-52.
3. World Health Organization (WHO) - Guidelines for the Treatment of Treponema pallidum (Syphilis). WHO, Geneva, 2016.